148 related articles for article (PubMed ID: 27087021)
21. Delivery of bortezomib with nanoparticles for basal-like triple-negative breast cancer therapy.
Shen S; Du XJ; Liu J; Sun R; Zhu YH; Wang J
J Control Release; 2015 Jun; 208():14-24. PubMed ID: 25575864
[TBL] [Abstract][Full Text] [Related]
22. Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.
Franke NE; Kaspers GL; Assaraf YG; van Meerloo J; Niewerth D; Kessler FL; Poddighe PJ; Kole J; Smeets SJ; Ylstra B; Bi C; Chng WJ; Horton TM; Menezes RX; Musters RJ; Zweegman S; Jansen G; Cloos J
Oncotarget; 2016 Nov; 7(46):74779-74796. PubMed ID: 27542283
[TBL] [Abstract][Full Text] [Related]
23. Enhancement of the intestinal absorption of bortezomib by self-nanoemulsifying drug delivery system.
Mahmoudian M; Valizadeh H; Löbenberg R; Zakeri-Milani P
Pharm Dev Technol; 2020 Mar; 25(3):351-358. PubMed ID: 31810410
[No Abstract] [Full Text] [Related]
24. Structural characterization of functionalized gold nanoparticles for drug delivery in cancer therapy: a NMR based approach.
Coelho SC; Rangel M; Pereira MC; Coelho MA; Ivanova G
Phys Chem Chem Phys; 2015 Jul; 17(29):18971-9. PubMed ID: 26126833
[TBL] [Abstract][Full Text] [Related]
25. Bortezomib-loaded solid lipid nanoparticles: preparation, characterization, and intestinal permeability investigation.
Mahmoudian M; Valizadeh H; Zakeri-Milani P
Drug Dev Ind Pharm; 2018 Oct; 44(10):1598-1605. PubMed ID: 29874944
[TBL] [Abstract][Full Text] [Related]
26. Bortezomib-Encapsulated Dual Responsive Copolymeric Nanoparticles for Gallbladder Cancer Targeted Therapy.
Chen M; Juengpanich S; Li S; Topatana W; Lu Z; Zheng Q; Cao J; Hu J; Chan E; Hou L; Chen J; Chen F; Liu Y; Jiansirisomboon S; Gu Z; Tongpeng S; Cai X
Adv Sci (Weinh); 2022 Mar; 9(7):e2103895. PubMed ID: 35068071
[TBL] [Abstract][Full Text] [Related]
27. The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.
Arkwright R; Pham TM; Zonder JA; Dou QP
Expert Opin Drug Discov; 2017 Feb; 12(2):225-235. PubMed ID: 27917682
[TBL] [Abstract][Full Text] [Related]
28. Noninvasive radiofrequency field destruction of pancreatic adenocarcinoma xenografts treated with targeted gold nanoparticles.
Glazer ES; Zhu C; Massey KL; Thompson CS; Kaluarachchi WD; Hamir AN; Curley SA
Clin Cancer Res; 2010 Dec; 16(23):5712-21. PubMed ID: 21138869
[TBL] [Abstract][Full Text] [Related]
29. Preparation and characterization of nanoliposomal bortezomib formulations and evaluation of their anti-cancer efficacy in mice bearing C26 colon carcinoma and B16F0 melanoma.
Korani M; Ghaffari S; Attar H; Mashreghi M; Jaafari MR
Nanomedicine; 2019 Aug; 20():102013. PubMed ID: 31103736
[TBL] [Abstract][Full Text] [Related]
30. Biological characterization of cetuximab-conjugated gold nanoparticles in a tumor animal model.
Kao HW; Lin YY; Chen CC; Chi KH; Tien DC; Hsia CC; Lin WJ; Chen FD; Lin MH; Wang HE
Nanotechnology; 2014 Jul; 25(29):295102. PubMed ID: 24990295
[TBL] [Abstract][Full Text] [Related]
31. Preparation and characterization of cyclodextrin nanosponges for bortezomib delivery.
Allahyari S; Valizadeh H; Roshangar L; Mahmoudian M; Trotta F; Caldera F; Jelvehgari M; Zakeri-Milani P
Expert Opin Drug Deliv; 2020 Dec; 17(12):1807-1816. PubMed ID: 32729739
[TBL] [Abstract][Full Text] [Related]
32. Encapsulation of docetaxel into PEGylated gold nanoparticles for vectorization to cancer cells.
François A; Laroche A; Pinaud N; Salmon L; Ruiz J; Robert J; Astruc D
ChemMedChem; 2011 Nov; 6(11):2003-8. PubMed ID: 21834092
[TBL] [Abstract][Full Text] [Related]
33. A versatile nanoplatform for synergistic combination therapy to treat human esophageal cancer.
Wang XS; Kong DJ; Lin TY; Li XC; Izumiya Y; Ding XZ; Zhang L; Hu XC; Yang JQ; Gao SG; Lam KS; Li YP
Acta Pharmacol Sin; 2017 Jun; 38(6):931-942. PubMed ID: 28552907
[TBL] [Abstract][Full Text] [Related]
34.
Rani S; Sahoo RK; Kumar V; Chaurasiya A; Kulkarni O; Mahale A; Katke S; Kuche K; Yadav V; Jain S; Nakhate KT; Ajazuddin ; Gupta U
Mol Pharm; 2023 Jan; 20(1):524-544. PubMed ID: 36306447
[TBL] [Abstract][Full Text] [Related]
35. Transferrin surface-modified PLGA nanoparticles-mediated delivery of a proteasome inhibitor to human pancreatic cancer cells.
Frasco MF; Almeida GM; Santos-Silva F; Pereira Mdo C; Coelho MA
J Biomed Mater Res A; 2015 Apr; 103(4):1476-84. PubMed ID: 25046528
[TBL] [Abstract][Full Text] [Related]
36. Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma.
Yoshida T; Ri M; Kinoshita S; Narita T; Totani H; Ashour R; Ito A; Kusumoto S; Ishida T; Komatsu H; Iida S
PLoS One; 2018; 13(5):e0196780. PubMed ID: 29738534
[TBL] [Abstract][Full Text] [Related]
37. Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.
Franke NE; Niewerth D; Assaraf YG; van Meerloo J; Vojtekova K; van Zantwijk CH; Zweegman S; Chan ET; Kirk CJ; Geerke DP; Schimmer AD; Kaspers GJ; Jansen G; Cloos J
Leukemia; 2012 Apr; 26(4):757-68. PubMed ID: 21941364
[TBL] [Abstract][Full Text] [Related]
38. Inducing cell cycle arrest and apoptosis by dimercaptosuccinic acid modified Fe3O4 magnetic nanoparticles combined with nontoxic concentration of bortezomib and gambogic acid in RPMI-8226 cells.
Zhang W; Qiao L; Wang X; Senthilkumar R; Wang F; Chen B
Int J Nanomedicine; 2015; 10():3275-89. PubMed ID: 25995634
[TBL] [Abstract][Full Text] [Related]
39. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
Nawrocki ST; Carew JS; Pino MS; Highshaw RA; Andtbacka RH; Dunner K; Pal A; Bornmann WG; Chiao PJ; Huang P; Xiong H; Abbruzzese JL; McConkey DJ
Cancer Res; 2006 Apr; 66(7):3773-81. PubMed ID: 16585204
[TBL] [Abstract][Full Text] [Related]
40. Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines.
Takahashi K; Inukai T; Imamura T; Yano M; Tomoyasu C; Lucas DM; Nemoto A; Sato H; Huang M; Abe M; Kagami K; Shinohara T; Watanabe A; Somazu S; Oshiro H; Akahane K; Goi K; Kikuchi J; Furukawa Y; Goto H; Minegishi M; Iwamoto S; Sugita K
PLoS One; 2017; 12(12):e0188680. PubMed ID: 29236701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
